Autoimmune Antibody and Coagulation Testing — CPB 0662 | AETNA Coverage Update

Aetna modified CPB 0662 covering autoimmune antibody and coagulation testing, effective December 9, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its autoimmune antibody and coagulation testing coverage policy under CPB 0662 Aetna system. The revision clarifies which von Willebrand disease (VWD) assays qualify as medically necessary and which tests now carry an experimental designation — including CPT codes 0279U, 0280U, 0283U, and 0284U on the covered side, and 0275U and 0281U as non-covered. If your lab, hematology practice, or coagulation testing team bills these Proprietary Laboratory Analyses (PLA) codes for Aetna members, this update changes your reimbursement exposure immediately.

Quick-Reference Table

Aetna Von Willebrand Disease Coagulation Testing Coverage Criteria and Medical Necessity Requirements 2025

The Aetna coagulation testing coverage policy under CPB 0662 establishes medical necessity for four specific VWD assays. Each one maps to a discrete clinical scenario. None of them function as open-ended VWD workup codes — Aetna wants specific diagnostic suspicion documented before you bill them.

CPT 0279U and 0280U — VWF collagen binding assays (Versiti VWF Collagen III Binding and Collagen IV Binding) — are covered when a member is suspected of type 2A, 2B, or 2M VWD and needs additional testing to confirm the diagnosis. The ICD-10 codes D68.020, D68.021, and D68.022 map directly to these subtypes. If the chart doesn't document one of those specific subtypes as the clinical suspicion, your medical necessity argument falls apart.

CPT 0284U — the VWF:FVIII binding assay (Versiti VWD Type 2N Binding) — is covered specifically for members suspected of type 2N VWD (D68.023). This is a narrow indication. Type 2N mimics mild hemophilia A, so the clinical picture may suggest hemophilia before VWD is on the differential. Make sure the ordering physician's documentation names type 2N suspicion explicitly — not just "bleeding disorder, rule out."

CPT 0283U — VWF type 2B platelet-binding evaluation — is covered to determine VWD type in members already diagnosed with VWD (D68.00, D68.09, or the full D68.02x series). This one works differently from the others. The member needs an established VWD diagnosis first. Billing 0283U on a suspected-but-unconfirmed VWD member is a claim denial waiting to happen.

The policy does not mention prior authorization requirements for the covered codes, but that doesn't mean your plan isn't requiring it. Check the member's specific plan benefits before assuming clean billing. For high-cost PLA codes like these, a quick prior auth check is worth the two minutes.

Aetna Coagulation Testing Exclusions and Non-Covered Indications

This is where the policy gets expensive if you're not paying attention.

Antiprothrombin antibody testing is experimental under CPB 0662. No CPT code maps cleanly to this in the policy's covered list. If your team has been billing antiprothrombin antibody workups for Aetna members and expecting reimbursement, stop and audit those claims.

CPT 0275U (Versiti Heparin-Induced Thrombocytopenia-PEA, platelet antibody reactivity by flow cytometry) is explicitly not covered. This PLA code is a Versiti-specific HIT assay. If you bill 0275U for an Aetna member, the denial is written into the policy. There's no medical necessity argument to make here — the policy classifies it as experimental, investigational, or unproven.

CPT 0281U (VWF propeptide antigen, Versiti VWF Propeptide Antigen) is also not covered. Aetna's position is that this assay — used to diagnose VWD type 1C — lacks established clinical value. If your lab performs VWF propeptide testing as part of a VWD workup, you cannot bill 0281U to Aetna and expect payment. Document this in your payer-specific fee schedule notes.

Detection of elevated factor VIII and VWF levels for acute ischemic stroke risk assessment is experimental. No CPT code is listed for this specific indication, but if you're running VWF panels with a stroke-risk framing in the clinical notes, expect Aetna to push back. The diagnosis codes D68.00–D68.09 won't save the claim if the indication reads like stroke risk screening.

The real issue with experimental designations is downstream. If a patient receives ABN-equivalent notice and pays out of pocket, that's a patient relations problem. If no notice was given and the claim denies, that's a compliance problem. Know which codes are in the experimental bucket before you order them for an Aetna member.

Coverage Indications at a Glance

Aetna Coagulation Testing Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Coagulation Testing Under CPB 0662

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Not Covered / Experimental CPT Codes

Other CPT Codes Related to CPB 0662

These codes appear in the policy but are listed as contextually related — not specifically covered or excluded under the VWD criteria above. Verify medical necessity criteria apply before billing these to Aetna.

Key ICD-10-CM Diagnosis Codes